Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics.
Tontodonati M, Cento V, Polilli E, Colabattista C, Cascella R, Sciotti M, Di Giammartino D, Trave F, Di Maio VC, Monarca R, Di Candilo F, Prinapori R, Rastrelli E, Vecchiet J, Ceccherini-Silberstein F, Manzoli L, Giardina E, Perno CF, Parruti G. Tontodonati M, et al. Among authors: parruti g. New Microbiol. 2015 Oct;38(4):491-7. Epub 2015 Oct 20. New Microbiol. 2015. PMID: 26485008 Free article. Clinical Trial.
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Svicher V, Alteri C, Gori C, Salpini R, Marcuccilli F, Bertoli A, Longo R, Bernassola M, Gallinaro V, Romano S, Visca M, Ursitti A, Feasi M, Micheli V, Angelico M, Cassola G, Parruti G, Gubertini G, De Sanctis GM, Ceccherini-Silberstein F, Cappiello G, Spanò A, Perno CF. Svicher V, et al. Among authors: parruti g. Dig Liver Dis. 2010 Dec;42(12):902-7. doi: 10.1016/j.dld.2010.04.017. Epub 2010 Jun 19. Dig Liver Dis. 2010. PMID: 20621632
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
Parruti G, Polilli E, Sozio F, Cento V, Pieri A, Di Masi F, Mercurio F, Tontodonati M, Mazzotta E, Ceccherini-Silberstein F, Manzoli L, Perno CF. Parruti G, et al. Antiviral Res. 2010 Oct;88(1):124-7. doi: 10.1016/j.antiviral.2010.08.003. Epub 2010 Aug 11. Antiviral Res. 2010. PMID: 20708036
Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy.
Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, Agostinone A, Di Masi F, Congedo G, D'Antonio D, Granchelli C, D'Amario C, Carunchio C, Pippa L, Manzoli L, Volpi A; VZV Pain Study Group. Parruti G, et al. BMC Med. 2010 Oct 11;8:58. doi: 10.1186/1741-7015-8-58. BMC Med. 2010. PMID: 20937086 Free PMC article.
268 results